It is made available under a CC-BY 4.0 International license .

1	Social determinants of injection drug use-associated bacterial infections and
2	treatment outcomes: systematic review and meta-analysis
3	
4	Thomas D. Brothers <sup>1,2</sup> ; Dan Lewer <sup>1,3</sup> ; Matthew Bonn <sup>4,5</sup> ; Inhwa Kim <sup>6</sup> ; Emilie Comeau <sup>6</sup> ; Mary Figgatt <sup>7,8</sup> ;
5	William Eger <sup>9</sup> ; Duncan Webster <sup>2,10</sup> ; Andrew Hayward <sup>1,11</sup> ; Magdalena Harris <sup>12</sup>
6	
7	$^1$ UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology & Health Care, University
8	College London (UCL), London, UK
9	<sup>2</sup> Department of Medicine, Dalhousie University, Halifax, Canada
10	<sup>3</sup> Bradford Centre for Health Data Science, Bradford Institute for Health Research, Bradford, UK
11	$^4$ Canadian Association of People who Use Drugs (CAPUD), Dartmouth, Canada
12	<sup>5</sup> Canadian AIDS Society, Ottawa, Canada
13	<sup>6</sup> Dalhousie Medical School, Dalhousie University, Halifax, Canada

- <sup>7</sup>Department of Epidemiology, University of North Carolina, Chapel Hill, USA
- 15 <sup>8</sup>Center for AIDS Research, University of Alabama at Birmingham, Birmingham, USA
- <sup>9</sup>Joint Doctoral Program in Interdisciplinary Research on Substance Use, University of California San
- 17 Diego and San Diego State University, San Diego, USA
- 18 <sup>10</sup>Division of Infectious Diseases, Saint John Regional Hospital, Saint John, Canada
- <sup>11</sup>Health Equity and Clinical Governance Division, UK Health Security Agency, London, UK
- 20 <sup>12</sup>Department of Public Health, Environments and Society, London School of Hygiene and Topical
- 21 Medicine (LSHTM), London, UK

22

23 Address correspondence to: thomas.brothers.20@ucl.ac.uk or thomas.brothers@dal.ca (TDB)

It is made available under a CC-BY 4.0 International license .

## 25 ABSTRACT

- 26 Background: Individual injecting practices (e.g., intramuscular injecting, lack of skin cleaning) are
- 27 known risk factors for injection drug use-associated bacterial and fungal infections; however, social
- 28 contexts shape individual behaviours and health outcomes. We sought to synthesize studies
- assessing potential social determinants of injecting-related infections and treatment outcomes.
- 30 **Methods:** We searched five databases for studies published between 1 January 2000 and 18
- 31 February 18 2021 (PROSPERO CRD42021231411). We included studies of association (aetiology),
- 32 assessing social determinants, substance use, and health services exposures influencing
- 33 development of injecting-related infections and treatment outcomes. We pooled effect estimates
- 34 via random effects meta-analyses.
- 35 **Results:** We screened 4,841 abstracts and included 107 studies. Several factors were associated with
- 36 incident or prevalent injecting-related infections: woman/female gender/sex (adjusted odds ratio
- 37 [aOR] 1.57, 95% confidence interval [CI] 1.36-1.83; n=20 studies), homelessness (aOR 1.29, 95%CI
- 38 1.16-1.45; n=13 studies), cocaine use (aOR 1.31, 95%CI 1.02–1.69; n=10 studies), amphetamine use
- 39 (aOR 1.74, 95%Cl 1.39-2.23; n=2 studies), public injecting (aOR 1.40, 95%Cl 1.05–1.88; n=2 studies),
- 40 requiring injecting assistance (aOR 1.78, 95%Cl 1.40–2.27; n=8 studies), and use of opioid agonist
- 41 treatment (aOR 0.92, 95%CI 0.89–0.95; n=9 studies). Studies assessing outcomes during treatment
- 42 (e.g., premature hospital discharge) or afterward (e.g., rehospitalization; all-cause mortality)
- 43 typically had smaller sample sizes and imprecise effect estimates.
- 44 **Conclusions:** Injecting-related infections and treatment outcomes may be shaped by multiple social
- 45 contextual factors. Approaches to prevention and treatment should look beyond individual injecting
- 46 practices towards addressing the social and material conditions within which people live, acquire
- 47 and consume drugs, and access health care.

It is made available under a CC-BY 4.0 International license .

## 48 INTRODUCTION

49 Injecting-related bacterial and fungal infections cause significant morbidity and mortality among 50 people who inject drugs, with 6-32% of people reporting an infection in the past month and up to 51 64% reporting a skin and soft-tissue infection (SSTI) in the past year.<sup>1</sup> Incidence of these infections is increasing in North America, Europe, and Australia.<sup>2–5</sup> Specific drug preparation and injecting 52 53 practices (including subcutaneous or intramuscular injecting, reusing blunted or contaminated needles and syringes, and not sterilizing skin before injecting) are known risk factors.<sup>1,6</sup> Individual-54 55 level educational interventions have been developed to promote safer drug injecting techniques, but 56 these have shown inconsistent efficacy.<sup>7-9</sup> Individual-level interventions may have limited impact because drug injecting practices are shaped by social contexts and material resources.<sup>10</sup> For 57 example, people without secure housing are more likely to inject in public or unhygienic spaces (e.g., 58 abandoned buildings).<sup>10,11</sup> People with insufficient access to needle and syringe programs may need 59 to reuse contaminated equipment.<sup>10,12,13</sup> 60

61 Treatment of injection drug use-associated bacterial and fungal infections is also often

62 suboptimal.<sup>10,14–16</sup> People who inject drugs describe negative experiences of untreated pain and

63 withdrawal in health care settings, which discourages access to care.<sup>10,17–19</sup> Clinicians caring for

64 people with injecting-related infections describe not knowing how best to help.<sup>16,20</sup> Poor care

experiences and outcomes are also affected by social determinants and system-level factors.<sup>10,14,21,22</sup>

66 Most acute care hospitals do not integrate substance use and addiction care, and many hospitals

67 have abstinence-based policies that lead patients to surreptitiously use drugs (e.g., in locked

bathrooms) or leave the hospital prematurely.<sup>16,22–27</sup> As a result, risk of fatal opioid overdose is two

69 to four times higher in the days after hospital discharge compared to other times, <sup>27,28</sup> and

70 rehospitalizations with recurrent injecting-related infections are common.<sup>29,30</sup>

Prevention and treatment strategies for injecting-related infections may be greatly improved if clinicians and health systems look more broadly to the social and structural factors that shape individual injecting practices and treatment outcomes. Such approaches have informed prevention and treatment strategies for HIV<sup>31–34</sup> and hepatitis C virus<sup>32,35</sup>, and prevention strategies for opioid overdose<sup>33,36</sup>, but less is known about how social determinants influence injecting-related bacterial and fungal infections.<sup>10,37</sup>

To better understand and quantify the influence of social determinants on injecting-related
infections and treatment outcomes (and to identify opportunities for novel interventions to improve

It is made available under a CC-BY 4.0 International license .

79 prevention and treatment), we sought to systematically review and meta-analyse the quantitative

80 literature on this topic. This review seeks to answer the question, "Among people who inject drugs,

- 81 what social and structural factors influence the development of, treatment of, and outcomes of
- 82 injecting-related bacterial and fungal infections?"

## 83 **METHODS**

We registered (PROSPERO CRD42021231411) and published a protocol<sup>37</sup> and before conducting the 84 search. We modified the protocol after full-text review. The protocol specified a "mixed studies" 85 review of quantitative, gualitative, and mixed-methods sources.<sup>38</sup> As we identified more studies than 86 anticipated, we separately reviewed and synthesized quantitative and qualitative studies. Here, we 87 88 report the quantitative systematic review and meta-analyses. Qualitative results are reported elsewhere.<sup>10</sup> Our approach is informed by the Conducting Systematic Reviews and Meta-Analyses of 89 Observational Studies of Etiology (COSMOS-E)<sup>39</sup> guidance. We followed Preferred Reporting Items 90 for Systematic reviews and Meta-Analyses (PRISMA) reporting guidelines.<sup>40</sup> 91

### 92 Eligibility criteria

Eligibility criteria are detailed in the protocol.<sup>37</sup> Briefly, we included quantitative studies of 93 association (actiology).<sup>39,41</sup> published in peer-reviewed journals. We followed the Population. 94 Exposures, Outcomes approach.<sup>41</sup> "Participants" were people who inject psychoactive substances. 95 "Exposures" were social or environmental factors that could affect risk for developing infections or 96 97 influence their treatment. This includes social, economic, and political factors such as housing, 98 income, drug policies, and other socially-patterned exposures such as availability of (or use of) different substances, harm reduction services, drug treatment, and health care. Informed by a socio-99 ecological model (the "intersectional risk environment"<sup>33,34</sup>), we also considered socially-constructed 100 101 identities and locations within social power hierarchies, including by gender/sex and race/ethnicity.<sup>33</sup> 102 While some sociodemographic characteristics (like gender, sex, or age) may confer effects through 103 both biological and social-structural pathways, these are often interlinked and we expected that guantitative studies would not attempt to isolate purported biological-only effects.<sup>33,36</sup> Potential 104 differences by gender/sex may reflect structural sexism, and potential differences by race/ethnicity 105 may reflect structural racism.<sup>33,36,42</sup> "Outcomes" were injecting-related bacterial or fungal infections 106 107 (and any reported outcomes during and after treatment of these infections), including SSTI (abscess, 108 cellulitis, necrotizing fasciitis), sepsis or bacteraemia, vascular infections (endocarditis, septic 109 phlebitis), bone and joint infections (osteomyelitis, septic arthritis, discitis), and central nervous

It is made available under a CC-BY 4.0 International license .

- 110 system infections (epidural abscess, brain abscess, meningitis, encephalitis). We included studies
- 111 published between 1 January 2000 and 18 February 2021, in English or French.

### 112 Information sources, search strategy, and data management

- 113 We searched PubMed, EMBASE, Scopus, CINAHL, and PsycINFO databases. We supplemented this
- 114 with forward and backward citation chaining and included articles from the review team's personal
- files. We developed the final search strategy in consultation with a health sciences librarian
- 116 (Appendix 1).
- 117 Search results were uploaded into Covidence and automatically de-duplicated. Two reviewers (TDB
- 118 and either MB, EC, IK, or DL) screened abstracts against the inclusion criteria, resolving discrepancies
- 119 through consensus. TDB assessed full-text reports for inclusion and recorded reasons for exclusion.

### 120 Data collection

- 121 We developed and pilot-tested a data extraction form for studies with quantitative data. Data was
- 122 extracted by TDB and checked independently by WE or MF. We extracted data on:
- 123 First author and publication year
- Social and structural exposures included in the review
- Main exposure or estimand of the study (and whether all exposures assessed in our review
- 126 reflect the study estimand)
- 127 Infection types (e.g., SSTI, endocarditis, osteomyelitis, etc.)
- 128 Infection-related outcomes
- Country (city) where study took place
- 130 Sample size
- Sampling method (and parent study name, if applicable)
- 132 Data collection period
- 133 Inclusion criteria
- Proportion of sample that are women/female
- 135 Age of sample
- 136 Drugs used by  $\geq$ 50% of the sample

- 138 As suggested in COSMOS-E guidance<sup>39</sup>, we manually extracted both unadjusted and fully covariate-
- adjusted effect estimates (with 95% confidence intervals), wherever possible. Following Kaufman<sup>43</sup>,

It is made available under a CC-BY 4.0 International license .

140 we conceptualized unadjusted analyses as associative (e.g., "are people experiencing homelessness

141 more likely to have injecting-related infections?") and covariate-adjusted effect estimates as

142 attempting to identify causal relationships (aetiology; e.g., "does homelessness contribute to

143 injecting-related infections?").

144 Where summary effect estimates (e.g., odds ratios) were not reported, we extracted frequencies to 145 calculate unadjusted odds ratios and standard errors. When studies reported only stratified analyses 146 (e.g., separate effect estimates among women and men) we kept both effect estimates for meta-147 analyses. When studies reported highly related effect estimates (e.g., for measures of both 148 "lifetime" and "past six months" homelessness) from the same sample, we included only one in meta-analysis to avoid double-counting and documented reasons for inclusion or exclusion.<sup>44</sup> 149 150 Specifically, we selected the exposure-outcome pair with the most congruent timelines (e.g., "past 151 six months" for exposure and outcome). As most studies reported effect estimates in odds ratios, we 152 treated all relative effect estimates (including hazard ratios and rate ratios) as if they were odds 153 ratios for meta-analysis.<sup>39</sup> When studies did not report statistics for null or nonsignificant findings. 154 (instead reporting, e.g., "no associations found"), we recorded where this was reported but we could 155 not include these in meta-analyses.

### 156 Critical appraisal

We applied the Mixed Methods Appraisal Tool<sup>45</sup> (MMAT: which is designed for use with quantitative. 157 qualitative, and mixed-methods studies), following the "user guide".<sup>46</sup> We included all studies which 158 159 met both screening questions: "Are there clear research questions?" and "Do the collected data 160 allow to address the research questions?". For quantitative studies of association (aetiology), five 161 criteria questions focus on whether the sample is representative of the target population, potential 162 measurement error, if confounders are accounted for, and whether the exposure occurred as 163 intended. The MMAT is scored only once per study, but many studies contain multiple exposure-164 outcome analyses that might have differing risks of bias. We scored a question as "No" if any 165 exposure-outcome analysis in the study did not meet the criteria (e.g., if the timeline of exposure 166 and outcome ascertainment did not align for one of many exposures assessed). Also, the MMAT only 167 asks whether confounders were considered, not how they were selected or if they are appropriate. 168 We scored "Yes" for studies that included covariate-adjusted analyses, no matter how covariates 169 were selected. We assigned each study a score out of 5, by summing the questions answered "Yes". 170 We report MMAT scores for each study but did not otherwise use critical appraisal in syntheses.

It is made available under a CC-BY 4.0 International license .

#### 171 Meta-analyses

- 172 We conducted separate inverse variance meta-analyses for each exposure-outcome pair in R
- 173 (version 4.2.2), using the *meta* package.<sup>44</sup> We performed random-effects meta-analyses because we
- assumed there would be between-study heterogeneity (including different exposure and outcome
- definitions, study settings, and sampling frames).<sup>39</sup> We applied the DerSimonian-Laird estimator for
- 176  $\tau^2$ ,<sup>47</sup> with the Knapp-Harding adjustment (which assumes a t-distribution of the standard error of the
- 177 pooled effect size and reduces the chance of false positives).<sup>48</sup> We measured the percentage of total
- 178 statistical variability attributable to between-study heterogeneity using *l*<sup>2</sup> statistics.<sup>49</sup> We identified
- 179 individual effect estimates as outliers if its confidence interval did not overlap with the confidence
- 180 interval of the pooled effects (i.e., the effect size of the outlier is so extreme that it differs
- 181 significantly from the meta-analysis summary effect).<sup>50</sup>

## 182 **RESULTS**

## 183 Summary of included studies

- 184 The mixed-studies search identified 8,167 references; after de-duplication, we screened 4,841
- abstracts and 631 full-text reports. We reviewed 16 additional full-text reports identified outside the
- search (Appendix 2). We excluded four quantitative studies because they failed the MMAT screening
- 187 questions (Appendix 3).
- 188 We finally included 107 studies (Figure 1). There were 60 studies assessing incident or prevalent
- 189 infections; 26 studies assessing outcomes during treatment (e.g., in-hospital mortality, premature
- 190 hospital discharge); 29 studies assessing outcomes after treatment (e.g., infection-related
- 191 rehospitalization, all-cause mortality); and five studies assessing colonisation with pathogenic
- 192 bacteria.

It is made available under a CC-BY 4.0 International license .






Figure 1. PRISMA 2020 flow diagram of included studies in quantitative systematic review of injecting-related infections

- 195 See Table 1 for summary of included studies and Appendices 4-7 for detailed characteristics of each 196 study. Two studies incorporated fungal infections (fungaemia and endogenous endophthalmitis); the 197 remaining 105 studies focused only on bacterial infections. Among the 60 studies where the 198 outcome was incident or prevalent injecting-related infections, 83% (n=50) included SSTI and 199 samples were median 28.6% women/female. Among studies where the outcomes occurred during or 200 after infection treatment, most focused on endocarditis (73% and 86%, respectively) and 201 woman/female participants were more common (48.2% and 43.2%, respectively). Overall, most 202 studies were from North America, followed by Europe (especially the United Kingdom). Few studies 203 came from Asia (n=2) or Africa (n=1), and none from South America.
- 204 See Appendices 8-11 for full MMAT critical appraisal results. See Appendices 12-15 for all extracted
- 205 effect estimates and Appendix 16 for details of selecting and transforming effect estimates for
- 206 inclusion in meta-analyses.

It is made available under a CC-BY 4.0 International license .

Characteristic	Level	Studies on incident or prevalent infections	Studies on outcomes during treatment for infection	Studies on outcomes after infection	Studies on colonization
Studies (n)		60 studies	26 studies	29 studies	5 studies
Sample sizes (no. of participants)	Median (range)	623 (45 – 60,529)	244 (20 – 605,859)	125 (19 – 27,432)	282 (78 – 497)
Age (mean or median), years	Median (range)	37 (27.5 – 47.1)	38 (25.8 – 47.2)	35.9 (28.5 – 46)	40.5 (38.7 – 47.6)
Gender/sex (% women/female)	Median (range)	28.6% (0.0% - 77%)	43.2% (2.9% - 69.0%)	48.2% (12.5% - 70%)	21.1% (16.0% -41.0%)
Infection syndrome <sup>a</sup>	No. (%) of studies				
	Skin and soft-tissue infections	50 (83%)	13 (50%)	4 (14%)	-
	Endocarditis	14 (23%)	19 (73%)	25 (86%)	-
	Sepsis/bacteraemia	5 (8%)	6 (23%)	3 (10%)	-
	Osteomyelitis	4 (7%)	9 (35%)	7 (24%)	-
	Septic arthritis	3 (5%)	6 (23%)	4 (14%)	-
	Spinal epidural abscess	2 (3%)	2 (8%)	3 (10%)	-
	Other	Pneumonia: 1 (2%)	Fungemia: 2 (8%) Pneumonia: 1 (4%) Botulism: 1 (4%) Endophthalmitis: 1 (4%)	Endophthalmitis: 1 (3%)	S. aureus colonization: 2 (40%) Methicillin-resistant S. aureus (MRSA): 5 (100%)
	Not specified	3 (5%)	0	0	0
	Multiple	9 (15%)	9 (35%)	7 (24%)	2 (40%)
Country	No. (%) of studies				
	United States	25 (42%)	18 (69%)	18 (62%)	3 (60%)
	Canada	11 (18%)	3 (12%)	3 (10%)	0
	United Kingdom	12 (20%)	2 (8%)	1 (3%)	1 (20%)
	Australia	1 (2%)	0	2 (7%)	0
	France	1 (2%)	0	0	0
	Germany	1 (2%)	0	0	0
	India	1 (2%)	0	0	0
	Sweden	1 (2%)	0	1 (3%)	0
	Switzerland	1 (2%)	1 (4%)	0	1 (20%)

207 Table 1. Summary of included studies in quantitative systematic review on injecting-related bacterial and fungal infections.

	Thailand	1 (2%)	0	0	0
	South Africa	0	1 (4%)	0	0
	Spain	0	1 (4%)	0	0
Publication year	No. (%) of studies				
	2018-2021	18 (30%)	15 (58%)	26 (90%)	2 (40%)
	2014-2017	16 (27%)	1 (4%)	2 (7%)	1 (20%)
	2010-2013	11 (18%)	4 (15%)	1 (3%)	1 (20%)
	2006-2009	8 (13%)	3 (12%)	0	1 (20%)
	2000-2005	7 (12%)	2 (8%)	0	0
No estimand or primary exposure not specified <sup>b</sup>	No. (%) of studies	30 (50%)	16 (62%)	11 (38%)	5 (100%)

<sup>a</sup>Total adds up to greater than 100% as several studies included more than one infection syndrome

<sup>b</sup>These are studies that did not aim to model a specific exposure or treatment effect as accurately as possible, but rather aimed to identify "factors associated with" an outcome. They either tested several unadjusted analyses (e.g., in case-control study) or tested multiple exposures at once in multivariable regression (e.g., stepwise regression, without a hypothesis or main exposure).

It is made available under a CC-BY 4.0 International license .

### 208 Incident or prevalent injecting-related infections

- 209 Sixty studies assessed factors associated with incident or prevalent injecting-related infections,
- 210 including sociodemographic factors (gender/sex, age, race/ethnicity, education,
- 211 income/employment, relationship status, migration), social and housing support characteristics
- 212 (incarceration, sex work, unstable housing/homelessness, food insecurity, health insurance),
- substance use-related factors (overdose history, heroin use, heroin formulation [i.e., tar vs. powder],
- 214 prescription-type opioids, cocaine [including crack and powder], amphetamines [including
- 215 methamphetamines], prescription-type stimulants, novel psychoactive stimulants,
- 216 speedball/goofball use, alcohol, smoking), drug policy and injecting contexts (drug policy changes,
- 217 drug purchasing network, public injecting, use of shooting galleries, police contacts/arrests,
- requiring or receiving injecting assistance, injecting with others), and harm reduction and drug
- treatment (needle and syringe programs, opioid agonist treatment, supervised consumption sites).
- 220 See Figure 2 for a summary of exposures and associated meta-analytic effect estimates. See Figure 3
- 221 for forest plots of unadjusted and adjusted effect estimates for three selected exposures:
- incarceration history, unstable housing or homelessness, and needle and syringe program use. See
- 223 Appendix 17 for full results, including forest plots for each exposure.
- 224 Briefly, we identified evidence to support associations between several factors with incident or
- 225 prevalent injecting-related infections, in meta-analyses of covariate-adjusted effect estimates:
- 226 woman/female gender/sex (adjusted odds ratio [aOR] 1.57, 95% confidence interval [CI] 1.36-1.83; I<sup>2</sup>
- 47%; n=20 studies), unstable housing and homelessness (aOR 1.29, 95%CI 1.16-1.45; I<sup>2</sup>9%; n=13
- studies; Figure 3), cocaine use (aOR 1.31, 95%Cl 1.02–1.69; l<sup>2</sup> 75%; n=10 studies), amphetamine use
- 229 (aOR 1.74, 95%Cl 1.39-2.23; l<sup>2</sup> 0%; n=2 studies), public injecting (aOR 1.40, 95%Cl 1.05–1.88; l<sup>2</sup> 0%;
- n=2 studies), requiring/receiving injecting assistance (aOR 1.78, 95%Cl 1.40-2.27; l<sup>2</sup> 48%; n=8
- studies), and use of opioid agonist treatment (aOR 0.92, 95%CI 0.89–0.95; I<sup>2</sup> 50%; n=9 studies). For
- several other exposures, we identified evidence to support an association only in meta-analyses of
- 233 unadjusted (but not covariate-adjusted) effect estimates: lower income/unemployment (unadjusted
- 234 odds ratio [uOR] 1.44, 95%Cl 1.22-1.71; l<sup>2</sup> 79%; n=16 studies), incarceration history (uOR 1.27, 95%Cl
- 235 1.06-1.53; l<sup>2</sup> 81%; n=6 studies; Figure 3), sex work (uOR 1.49, 95%Cl 1.06-2.09; l<sup>2</sup> 89%; n=8 studies),
- heroin use (uOR 1.35, 95%Cl 1.13-1.61; I<sup>2</sup> 75%; n=20 studies), speedball (heroin and cocaine
- together) or goofball (heroin and methamphetamines together) use (uOR 1.34, 95%Cl 1.15-1.57; I<sup>2</sup>
- 238 51%; n=12 studies). For all other exposures (including needle and syringe program use, aOR 0.75,

- 239 95%Cl 0.54-1.03; Figure 3), meta-analyses of unadjusted or covariate-adjusted effect estimates
- 240 included null effect within their 95% confidence intervals.

xposure	Unadjusted Odds Ratio (95% CI)	No. of Studies	Adjusted Odds Ratio (95% Cl)	No. of Studies	Odds Ratios (95% CI)
Demographic characteristics	(95% CI)		(95% CI)		······
Gender/sex (womean/female)	1.56 (1.34-1.82)	27	1.57 (1.36-1.83)	20	*
Age (older)	1.00 (0.99-1.01)	32	1.00 (0.89-1.10)	20	
Race/ethnicity (white)	1.14 (0.90-1.44)	17	1.15 (0.92-1.44)	11	-
Education (more)	0.87 (0.76-0.99)	9	0.86 (0.13-5.55)	4	
Income/employment (unemployed/low income)	1.44 (1.22-1.71)	16	1.16 (0.81-1.65)	7	
Relationship status (married)	0.61 (0.00-377.00)	2	0.38 (0.17-0.85)	1	<
Migration status (born outside UK)	1.20 (0.80-1.60)	1		0	
Social and housing support characteristics					
Incarceration history (yes)	1.27 (1.06-1.53)	6	1.60 (0.99-2.59)	2	
Sex work (yes)	1.44 (1.06-2.09)	9	1.58 (0.72-3.50)	6	
Unstable housing/homelessness (yes)	1.34 (1.20-1.49)	29	1.29 (1.16-1.45)	13	
Food insecurity (yes)	1.76 (0.84-3.68)	1		0	
Health insurance (Medicaid vs. other)	0.79 (0.18-3.56)	1		Ō	
Substance use					
Overdose history (yes)	2.28 (0.42-12.26)	2	1.87 (0.25-14.06)	2	
Heroin formulation (tar vs. powder)	7.44 (0.31-176.41)	2	3.65 (0.00-15058.18)	2	
Heroin injecting (any/frequent vs. none/less)	1.53 (1.29-1.82)	20	1.28 (0.95-1.74)	7	
Cocaine injecting, all types (any/frequent vs. none/less)	1.42 (1.25-1.61)	27	1.31 (1.02-1.69)	10	
Crack (base) cocaine injecting (any/frequent vs. none/less)	1.55 (1.33-1.80)	9	1.30 (0.80-2.13)	3	
Powder (hydrochloride) cocaine injecting (any/frequent vs. none/less)	1.35 (1.00-1.83)	7	1.78 (1.14-2.78)	1	
Amphetamine injecting (any/frequent vs. none/less)	0.90 (0.54-1.48)	11	1.74 (1.39-2.23)	2	
Methylphenidate injecting (any/frequent vs. none/less)	0.73 (0.19-2.82)	2		0	
Speedball or goofball injecting (any/frequent vs. none/less)	1.34 (1.15-1.57)	12	1.35 (0.38-4.77)	2	
Alcohol use (any/hazardous vs. none/less)	0.94 (0.77-1.14)	7	0.59 (0.13-2.67)	3	
Drug policy and injecting context			5100 (0110 £107)	~	
Injecting in public (yes)	1.54 (1.27-1.86)	4	1.40 (1.05-1.88)	2	
Shooting gallery use (yes)	0.84 (0.17-4.02)	2	1.33 (0.31-5.73)	1	
Police contacts and arrest history (yes)	1.16 (0.85-1.59)	9	1.19 (0.61-2.31)	4	
Assisted injecting (receiving or requiring vs. not)	2.09 (1.61-2.71)	8	1.78 (1.40-2.27)	8	
Injecting with others (yes)	1.44 (0.88-2.34)	7	2.55 (0.01-769.91)	2	
Harm reduction and drug treatment	(2100 210 1)		2.00 (0.01100.01)		
Needle and syringe program use (any/frequent vs. none/less)	0.75 (0.54-1.05)	7	0.75 (0.54-1.03)	6	_
Opioid agonist treatment (current/recent vs. not)	0.71 (0.62-0.81)	10	0.92 (0.89-0.95)	9	
Supervised consumption site use (any/frequent vs. none/less)	0.74 (0.17-3.26)	3	0.59 (0.29-1.19)	1	

242 243 244

Figure 2. Summary of exposures and meta-analytic effect estimates among studies where outcome is incident or prevalent injecting-related bacterial infection.

Cl: confidence interval. See supplementary appendices for data on the remaining exposures (injecting prescription-type opioids; injecting other prescription-type stimulants, injecting novel psychoactive stimulants, smoking, drug policy changes, for drug-purchasing network) that could not be presented as single summary effect estimates.

Study	Unadjusted Odds Ratio Weight	Adjusted Odds Ratio Weight	Homelessness or unstable housing	Study	Unadjus Odds Ra	tio Weight	Adju Odds	Ratio V	Veight	Inc	arceration histor	y
Wilson 2002	(95% Cl) 0.78 (0.46-1.32) 3%	(95% CI)		Lloyd-Smith 2005	(95% C 1.65 (1.30-	l) 2.10) 16%		6 CI) 30-2.20)	30%		_	
Lloyd-Smith 2005	1.41 (1.10-1.80) 7%		<b>_</b> _					,			-	
Sierra 2006	4.33 (1.50-12.50) 1%		<b>&gt;</b>	Hope 2010	1.00 (0.87-	1.13) 20%				_	-	
Hope 2008	1.54 (1.10-2.17) 5%		<b>_</b>	Milloy 2010	1.56 (1.32-	1.85) 18%	1.56 (1.3	31-1.85)	70%		-	
Lloyd-Smith 2008	1.56 (1.15-2.12) 6%	1.49 (1.10-2.03) 9%		D-W-10040							-	
Phillips 2008	1.00 (0.43-2.32) 1%	1.00 (0.43-2.33) 1%		Pollini 2010	1.31 (0.88-	1.94) 11%					-	
Lloyd-Smith 2009	1.61 (1.17-2.22) 5%	1.38 (1.02-1.88) 9%		Dunleavy 2017	1.03 (0.83-	1.28) 17%				_	-	
Hope 2010	1.23 (1.08-1.41) 10%	1.18 (1.05-1.33) 38%	*	Darea 0000							-	
Lloyd-Smith 2010	1.65 (1.08-2.53) 4%	1.26 (0.79-2.02) 4%		Doran 2020	1.28 (1.10-	1.50) 19%					-	
Milloy 2010	1.24 (0.98-1.56) 7%	1.30 (1.01-1.67) 13%										_
Phillips 2010	1.22 (0.35-4.27) 1%			Random effects model	1.27 (1.06-	52	4 00 10	~ ~ ~ ~				
Pollini 2010	1.74 (0.71-4.26) 1%			Random effects model	1.27 (1.06-	1.53)	1.60 (0.9	99-2.59)				
Lloyd-Smith 2012 (Men only)	1.60 (1.18-2.17) 6%	1.37 (0.98-1.92) 8%		Heterogeneity		81%			0%			
Lloyd-Smith 2012 (Women only)	1.69 (1.09-2.61) 4%	1.12 (0.69-1.82) 4%								r i	1	
Hope 2014 (Cellulitis)	1.39 (0.99-1.94) 5%									0.5 1	2	5
Hope 2015 (Cellulitis)	1.36 (1.04-1.78) 6%	2.17 (1.36-3.45) 4%	<b></b>								∽ ds Ratios (95% Cl	
Smith 2015	0.80 (0.30-2.14) 1%									00	13 110103 (3070 01	/
Betts 2016	1.39 (0.97-1.99) 7%					Unadjusted		Adjusted				
Dahlman 2017	1.26 (0.49-3.23) 1%			Study		Odds Ratio	Veight	Odds Ratio	Weig	ht Need	le and syringe prog	gram use
Phillips 2017	0.78 (0.39-1.56) 2%	0.53 (0.22-1.27) 1%		Binswanger 2000		(95% CI) 0.94 (0.40-2.20)	6%	(95% CI)				-
Summers 2017	3.09 (1.53-6.24) 2%	1.37 (0.38-4.94) 1%	•• \bullet	Ei_L 2012		4 00 (0 70 4 07)				-	_	
Wurcel 2018 (Men only)	0.68 (0.30-1.56) 1%			Fink 2013		1.02 (0.76-1.37)	19%	0.91 (0.65-1.2	209	6		
Wurcel 2018 (Women only)	2.34 (0.77-7.12) 1%	1.99 (0.48-8.27) 0%	<b>_</b> ••>	Dunleavy 2017 (Needle and syring	e uptake)	0.65 (0.53-0.80)	22%	0.72 (0.58-0.8	9) 289	6	-	
Baltes 2020	0.80 (0.27-2.38) 1%			Dunleavy 2017 (Other equipment u	uptake)	0.71 (0.58-0.87)	23%	0.77 (0.63-0.9	(5) 299	6		
Doran 2020 (C&P)	1.23 (0.80-1.90) 4%					secondestates are the			stones		_	
Doran 2020 (UAM)	1.10 (1.00-1.20) 11%		-	Wurcel 2018 (Men only)		1.43 (0.80-2.56)	10%	1.31 (0.65-2.6	3) 7%			_
Roux 2020	2.22 (1.19-4.15) 2%			Wurcel 2018 (Women only)		0.49 (0.19-1.24)	5%	0.27 (0.07-1.0	1) 2%	<b>E</b>	-	
Shah 2020	1.38 (0.61-3.11) 1%		-	Noroozi 2019		0.46 (0.30-0.71)	14%	0.50 (0.32-0.7	(8) 149		-	
Thonnings 2020	0.74 (0.38-1.45) 2%			THE SAL BY IS		0.10 (0.00 0.1 1)	1474	0.00 (0.02-0.1	0) 143			
Wright 2020	1.24 (0.79-1.96) 3%											
Random effects model	1 24 (1 20 1 40)	1.29 (1.16-1.44)	-	Random effects model		0.75 (0.54-1.05)		0.75 (0.54-1.0	3)		-	
Heterogeneity	1.34 (1.20-1.49) 43%	1.29 (1.16-1.44) 9%	*	Heterogeneity			64%		479	6		
neterogeneity	43%	9%										
		c	0.2 0.5 1 2 5								0.5 1 2	
			Odds Ratios (95% CI)							0.2	0.5 1 2 Odds Ratios (95%	C/) 5

247 248 249

Figure 3. Forest plots for meta-analyses of selected exposures among studies where outcome is incident or prevalent injecting-related bacterial or fungal infections. In the panel on the left, the exposure is unstable housing or homelessness; in the panel on the top right, it is incarceration history; in the panel on the bottom right, the exposure is needle and syringe program use. Cl: confidence interval. C&P: Care & Prevent cohort, UAM: Unlinked Anonymous Monitoring survey cohort (both reported in Doran 2020).

It is made available under a CC-BY 4.0 International license .

## 250 Outcomes occurring during treatment for injecting-related infections

- 251 We identified 26 studies assessing several outcomes during treatment/care of injecting-related bacterial
- infections. See Table 2 for the eight outcomes and list of exposures assessed in relation to each.

# Table 2. Summary of outcomes and associated exposures assessed among studies where outcome occurs during treatment for injecting-related infections.

Outcomes	Exposures assessed	Number of studies
Health care-seeking for injecting-related infections	gender/sex; age; income/employment; sex work; unstable housing; incarceration; overdose history; migration status; heroin use; cocaine use; amphetamine use; opioid agonist treatment; supervised consumption site use	4
Self-treatment of abscess	gender/sex; age; race/ethnicity; unstable housing; heroin use; cocaine use; needle and syringe programs; several measures of access to health care (e.g., having a primary care provider or having health insurance)	2
Hospital admissions among people with an injecting-related SSTI	gender/sex; age; race/ethnicity; education; income/employment; sex work; migration status; unstable housing/homelessness; incarceration history; overdose history; heroin; cocaine; amphetamines; alcohol use; needle and syringe program use; access to health care (e.g., insurance, having a primary care provider); self-treatment of infections; hospital admission history	2
Premature hospital discharges, among people hospitalized with injecting-related infections	gender/sex; age; race/ethnicity; income/employment; unstable housing; overdose history; opioid use; cocaine; alcohol; other substance use; health care access; opioid agonist treatment; in- hospital addiction treatment; hospital characteristics; hospital policy; surgery during hospitalization	10
New/secondary bloodstream infections among people receiving antibiotic treatment	gender/sex; age; unstable housing and homelessness; substance use (heroin, stimulants, polysubstance use, other); substance use treatment; insertion of peripherally-inserted intravenous central catheters (PICC lines) for parenteral antimicrobial treatment	1
In-hospital death	gender/sex; age; race/ethnicity; overdose history; substance use (opioids, stimulants); health care access (insurance); hospital policies; surgery during hospital admission	5
Development of endogenous endophthalmitis	gender/sex; race/ethnicity; alcohol use; infection of central venous catheter	1
Respiratory failure among people with botulism	gender/sex; age	1

255 Studies assessing outcomes during treatment for injecting-related infections typically had smaller

256 sample sizes and imprecise effect estimates (compared to studies assessing incident or prevalent

It is made available under a CC-BY 4.0 International license .

- 257 injecting-related infections) and findings were inconsistent between studies. Many exposures were only
- assessed in one study, limiting meta-analyses.
- 259 See Appendix 18 for full results including several meta-analyses for studies in the section. Among
- 260 exposure-outcome pairs assessed in more than one study, we identified supporting evidence for only
- 261 one association. Lacking health insurance was associated with increased risk of premature hospital
- discharge (aOR 2.07, 95%Cl 1.09-3.91; l<sup>2</sup> 85%; n=4 studies), among people hospitalized with injecting-
- related infections in one U.S. study. In other country settings (e.g., United Kingdom or Canada), universal
- 264 public health insurance covers hospital services.

## 265 Outcomes occurring after initial treatment of injecting-related infection

- 266 We identified 29 studies assessing outcomes after initial treatment for injecting-related infections. See
- Table 3 for six outcomes, and which exposures were assessed in relation to each.
- Table 3. Summary of outcomes and associated exposures assessed among studies where outcome occurs after initial treatment
   for injecting-related infections.

Outcomes	Exposures assessed	Number of studies
Infection-related rehospitalization (after discharge from an initial hospital admission with injecting-related infections)	gender/sex; age; race/ethnicity; rural residency; substance use (injecting prescription opioids); opioid agonist treatment; other substance use treatment; hospital policy; premature hospital discharge against medical advice; cardiac surgery during admission	8
All-cause rehospitalization	gender/sex; age; race/ethnicity; unstable housing; access to healthcare (health insurance); substance use (heroin, cocaine, methamphetamine, other); opioid agonist treatment; other addiction treatment; hospital policies; antibiotic treatment models; surgery during hospital admission	9
Overdose-related rehospitalization	gender/sex; age; substance use; opioid agonist treatment; hospital policy	2
All-cause mortality	gender/sex; age; unstable housing; substance use (opioid, stimulant, polysubstance use); premature hospital discharge against medical advice; opioid agonist treatment; other addiction medicine treatment; hospital policy; surgery during hospital admission	14
Failure of outpatient parental antimicrobial therapy [OPAT]	age; discharge setting	3
Change in visual acuity following treatment for endogenous endophthalmitis	gender/sex; age	1

It is made available under a CC-BY 4.0 International license .

- 270 Studies assessing outcomes after treatment also typically had imprecise effect estimates and
- inconsistent findings between studies, and opportunities for meta-analyses were limited.

272 See Appendix 19 for full results including several meta-analyses amongst studies in this section. Only 273 two exposure-outcome associations were found to be significant in meta-analyses incorporating more 274 than one study. Woman/female gender/sex was associated with increased risk of all-cause 275 rehospitalization. Summary meta-analysis of three covariate-adjusted effect estimates was aOR 1.22 276 (95%Cl 1.08-1.38;  $l^2$  0%). One unadjusted effect estimate was nonsignificant at uOR 1.23 (95%Cl 0.77-277 1.96). Inpatient addiction medicine consultation (during hospitalization with injecting-related infections) 278 was associated with reduced risk of all-cause rehospitalization; summary of two unadjusted effect estimates was uOR 0.46 (95%Cl 0.33-0.63; I<sup>2</sup> 0%) and one fully-adjusted effect estimate was aOR 0.57 279

280 (95%Cl 0.38–0.86).

### 281 Colonisation with pathogenic bacteria

282 Five studies assessed factors associated with colonisation with Staphylococcus aureus or methicillin-

- resistant *S. aureus* among people who inject drugs: gender/sex; age; race/ethnicity; education;
- 284 employment; relationship status; unstable housing and homelessness; incarceration; substance use
- 285 (heroin, cocaine, crack, speedball, methamphetamines, prescription opioids; cannabis); public injecting;

injecting in groups; opioid agonist treatment; other addiction treatment; recent hospital admission; and

287 other (e.g. using public shower facilities). Several exposures had significant associations in single studies

- 288 (e.g., public injecting, injecting frequently with three or more people, sleeping at more than one place
- during the prior week), but none were significant in meta-analyses of multiple studies. See Appendix 20
- 290 for full results among studies on colonization.

# 291 **DISCUSSION**

In this systematic review and meta-analysis, we identified 107 studies that assessed social determinants,
 substance use, and health services factors in relation to injecting-related bacterial infections and

- treatment outcomes. Several individual-level injecting risk practices (i.e., intramuscular or subcutaneous
- injecting, more frequent injecting, and lack of skin cleaning) were already known to be risk factors for
- these infections,<sup>1</sup> and we were interested in the social contextual factors that can influence injecting
- 297 practices and treatment experiences. In meta-analyses, we found evidence that risk for injecting-related

It is made available under a CC-BY 4.0 International license .

298 infections was increased with woman/female gender/sex, less education, a history of incarceration, sex 299 work, unstable housing and homelessness, heroin use, cocaine use, public injecting, and requiring or 300 receiving injecting assistance. Among harm reduction and drug treatment factors, opioid agonist 301 treatment was associated with a modest reduction in risk (i.e., ~8% lower odds). Overall, there were 302 many more studies where the outcome was incident or prevalent injecting-related infections than there 303 were studies assessing health outcomes occurring during or after infection treatment (e.g., premature 304 hospital discharge; all-cause mortality). Most studies that focused on outcomes occurring during or after 305 infection treatment had small sample sizes and imprecise effect estimates, and most exposures assessed 306 in this setting were only addressed in one study (so could not be meta-analysed). While this review 307 incorporated a broad scope, there was insufficient evidence (with imprecise effect estimates) for many 308 potential exposures, and interpreting meta-analyses was limited by high clinical and statistical 309 heterogeneity. Nevertheless, the importance of social-structural factors on the risk of injecting-related 310 infections and their treatment suggests that future approaches to improving prevention and treatment 311 should look more broadly than individual-level injecting practices and engage with the social and 312 material conditions within which people live, acquire drugs, consume them, and access health care.

313 The findings of this quantitative systematic review and meta-analysis complement a qualitative systematic review and thematic synthesis, published recently by our group.<sup>10</sup> In the gualitative review. 314 315 we identified several potential mechanisms through which social-structural factors could influence risk 316 for injecting-related infections and poor treatment outcomes, including unregulated drug quality (e.g., 317 poorly soluble drugs or adulterants contributing to skin and vein damage), insufficient housing (e.g. 318 people not having access to running water to prepare drugs, or adequate lighting to find a vein), 319 criminalization and enforcement (e.g., people compromising their drug preparation practices and 320 rushing to inject their drugs intramuscularly to avoid police search and seizure), and operational 321 limitations on harm reduction services (e.g. insufficient funding, or geographic restrictions). We also 322 identified that harmful health care policies and practices lead to negative experiences of undertreated 323 pain and withdrawal that discourage people from accessing care until infections had worsened and 324 spread, or otherwise contribute to people leaving hospital prematurely against medical advice (before 325 their treatment is complete). In the quantitative meta-analyses reported here, we identified consistent 326 evidence of population-level effects for some of those exposures, but not for others. For example, here 327 we identified evidence to support an association between incident or prevalent injecting-related 328 infections with unstable housing or homelessness and injecting in public. A history of police contacts and

It is made available under a CC-BY 4.0 International license .

arrests may have been associated with risk for infections (aOR 1.19, 95%Cl 0.61-2.31), with imprecise
 confidence intervals that could include meaningful differences. However, this is measuring a different
 phenomenon than a concurrent police encounter contributing to a specific abscess for an individual.

332 In the qualitative review, participants highlighted the key role of harm reduction programs, like 333 sufficient needle and syringe program coverage and access to supervised consumption sites, in enabling 334 their ability to reduce risks for infection. Here, we did not identify evidence to support risk reduction 335 with use of needle and syringe programs (aOR 0.75, 95%Cl 0.54-1.03) or supervised consumption sites 336 (aOR 0.59, 95%Cl 0.29-1.19). Pooled effect estimates were imprecise and may include clinically 337 meaningful reductions (or increases) in risk. These statistics from (mostly) cross-sectional observational 338 studies may also show that needle and syringe programs and supervised consumption sites are 339 successfully engaging people at highest risk of bacterial infections. This same phenomenon was 340 observed in early research on HIV infection among people accessing needle and syringe programs.<sup>51–53</sup> In addition, there were two ecological studies (that we could not include in meta-analyses) showing a 341 reduction in injecting-related infections after people started accessing needle and syringe programs. A 342 343 study published after our search found that people who regularly attended supervised consumption sites in France were less likely to report a recent abscess (18% vs. 22%).<sup>54</sup> We identified that use of 344 opioid agonist treatment was associated with a modest reduction in risk for injecting-related infections 345 346 (aOR 0.92, 95%Cl 0.89-0.95). Three studies on opioid agonist treatment and incident injecting-related infections, published after our search, estimated similar effects.<sup>3,29,55</sup> 347

In the context of the social determinants of health (and the closely related concepts of structural 348 349 vulnerability and structural violence), we were interested in social identities and locations within societal power hierarchies which may enable or constrain the ability of people who inject drugs to 350 prevent injecting-related infections and/or access treatment.<sup>33,34</sup> We identified evidence to support 351 352 associations between some sociodemographic characteristics and risks of injecting-related bacterial 353 infections, including woman/female gender/sex, lower educational attainment, lower 354 income/unemployment, incarceration, and sex work. We did not identify evidence to support 355 associations with other characteristics, including by race/ethnicity. We conceptualized race as a proxy measure for the effects of structural racism<sup>42,43</sup>, and the absence of evidence identified here does not 356 357 necessarily mean that racism is not an important determinant of injecting-related infections or 358 treatment outcomes. While many studies considered sociodemographic characteristics as covariates in

It is made available under a CC-BY 4.0 International license .

regression models (e.g., 17 studies included effect estimates for race/ethnicity on incident/prevalent infections), few studies were designed specifically to model the effect of these exposures (e.g., only one study modelled race/ethnicity as a primary exposure). In studies that did not specify a main exposure or estimand (instead considering all available variables in stepwise regressions), the effect of "upstream" exposures (e.g., structural racism) may be inappropriately blocked or hidden by conditioning on potential mediating variables (e.g., income, employment, or housing status that may be patterned by structural racism).<sup>42,43</sup>

366 Women may face excess risks of bacterial infections in the context of gendered power dynamics, for 367 example that would lead them to "go second" and reuse contaminated equipment when injecting with male partners.<sup>33,56,57</sup> Women may be less likely to know how to inject themself, and more likely to rely 368 369 on assisted-injecting (which could reduce risks of intramuscular injection and abscesses in some people, but was associated with increased risks of bacterial infections in this review).<sup>58,59</sup> Women may also be 370 less likely to engage with harm reduction programs (which are more likely to have been designed for 371 men); very few harm reduction programs (e.g., supervised consumptions sites) are gender-attentive or 372 373 gender-specific.<sup>33,60–62</sup> Some investigators have also hypothesized that excess risk of infections among 374 women is attributable to deeper peripheral veins, due to different distributions of adipose tissue (and so 375 women may have more difficulty accessing veins and may be more likely to inject in subcutaneous 376 tissue).<sup>6</sup> These differing risks are reflected in the greater proportion of woman/females in studies during 377 and after treatment of injecting-related infections compared to studies assessing risk of incident or 378 prevalent infections. Fewer studies focused on outcomes during and after treatment, which led to 379 inconsistent findings. For example, woman/female gender/sex appeared associated with higher risks of 380 all-cause rehospitalization but not infection-related rehospitalization, and it is unclear why this would be 381 the case.

We also found that several substances were associated with higher risks of injecting-related bacterial infections, this including frequent or any use (vs. less or no use) of injection heroin, cocaine, and amphetamines. Studies that compared "frequent" (typically "daily or more") use to less use did not consistently find that more frequent use of these substances was associated with greater risks of infections. Several studies also assessed specific formulations of unregulated drugs. Use of tar heroin (compared to powder heroin) was associated with nearly eight-fold increased risk of injecting-related bacterial infections in a covariate-adjusted analysis in one study<sup>63</sup>, and two-fold increased risk in a

It is made available under a CC-BY 4.0 International license .

second (ecological) study.<sup>64</sup> This may be because tar heroin is less soluble (leading to more undissolved 389 390 particulate matter that can damage veins) and also that tar heroin requires the addition of acidifiers to dissolve and prepare for injection (and overuse of acidifiers contributes to vein sclerosis).<sup>6,65,66</sup> "Crack" 391 392 cocaine (base) formulations also require the addition of acidifiers to prepare the drug solution for 393 injecting (while powder cocaine hydrochloride does not), but use of both crack and powder cocaine 394 were associated with increased risks in meta-analyses of unadjusted analyses. Other specific substances 395 were associated with increased risk of injecting-related infections in individual studies, including of 396 ethylphenidate (a novel synthetic stimulant, associated with high frequency of injecting). In research 397 external to this review, investigators have hypothesized that the North American drug supply transition 398 to fentanyl has driven increasing incidence of injecting-related infections, as fentanyl has a shorter halflife than heroin and is associated with more frequent injecting.<sup>2,67,68</sup> We identified no studies directly 399 400 assessing illicit fentanyl use and risks of infections; two studies published after our search found injecting-related infections to be more common among people who inject fentanyl.<sup>69,70</sup> Xylazine in the 401 402 North American unregulated drug supply has also recently emerged as a cause of unusual wounds and 403 infections; we identified no studies on xylazine here and we are not aware of any existing studies quantifying this risk.<sup>71,72</sup> 404

## 405 Limitations

406 This review has several important limitations. First, we only included studies where the outcomes were injecting-related infections or treatment outcomes, so we did not capture studies where the outcome 407 was risky injecting practices (e.g., lack of skin cleaning) that are associated with infections.<sup>73-75</sup> Second, 408 409 the inclusion of many exposures and outcomes (and, potentially, meta-analyses of unadjusted and 410 covariate-adjusted effect estimates for each exposure) could lead to false positive findings through 411 simply random chance (the so-called "multiple comparisons problem"). However, we wanted to take as 412 broad a scope as possible to identify potential social determinants. Third, summary effect estimates 413 from meta-analyses were likely not entirely accurate for several reasons: (a) we could not incorporate 414 "negative" or "null" effect estimates from several studies that reported no statistics (only that the 415 exposure and outcome were "not associated") or reported unadjusted associations but dropped the 416 variable in stepwise approaches to multivariable regression; (b) we combined effect estimates from 417 studies with high heterogeneity (with different exposure and outcome definitions, timelines, sampling strategies, inclusion criteria, and study settings) which was often reflected in high measures of between-418 study statistical heterogeneity (I<sup>2</sup> values); (c) most studies did not specify a hypothesis or estimand (and 419

It is made available under a CC-BY 4.0 International license .

420 most did not take a causal or prespecified approach to covariate selection), which meant that most 421 estimates did not come from studies trying to model as accurate as an effect as possible. Fourth, the 422 observational cohort, cross-sectional, and case-control studies included in this review rarely contributed 423 to understanding of mechanisms by which specific exposures affect the risk of infections or other treatment outcomes. This is one of the strengths of the complementary qualitative review.<sup>10</sup> Future 424 425 research focused on specific exposures and potential interventions could incorporate mixed-methods 426 and critical realist methods to improve understanding of how these risks come about.<sup>38,51–53</sup> Fifth, our 427 search did not include studies during the COVID-19 era, which may have changed the risk environment. 428 For example, a study published after our search showed rapid decline in incidence of injecting-related 429 infections coinciding with the implementation of COVID response measures in England, comprised of 430 decreased social mixing and temporary private accommodations for all people sleeping outside and in congregate shelters ("Everyone In" initiative).<sup>5</sup> 431

### 432 Conclusions

433 Injecting-related infections, their treatment, and subsequent outcomes are shaped by multiple social

434 determinants, substance use, and health services-related factors. Public health and clinical approaches

to prevention and treatment should look more broadly than individual injecting practices, towards

436 addressing the social and material conditions within which people live, acquire and consume drugs, and

437 access health care.

It is made available under a CC-BY 4.0 International license .

# 439 **ACKNOWLEDGMENTS**

We acknowledge that T.D.B., M.B., E.C. and I.K. live and work in Mi'kma'ki, the ancestral and unceded territory of the Mi'kmaq, and D.W. lives and works in unsurrendered and unceded territory and traditional lands of Wolastoqiyik. This territory is covered by the Treaties of Peace and Friendship which the Mi'kmaq and Wolastoqiyik Peoples first signed with the British Crown in 1725. The treaties did not deal with surrender of lands and resources but, in fact, recognized Mi'kmaq and Wolastoqiyik title and established the rules for what was to be an ongoing relationship between nations. We are Treaty people.

We thank Louise Gillis (Research Data Librarian at Dalhousie University) for helpful feedback and
assistance with our search strategy. We thank Ricky Bluthenthal (University of Southern California) and
Joseph Hayes (University College London) for helpful feedback on earlier drafts. We thank authors who
provided correspondence and/or further information about their studies: Kasha Bornstein, Dan
Ciccarone, Samantha Colledge-Frisby, Irina Ianache, Alison Ivey, Lisa Maher, David Marsh, Kristen Morin,
Viktor Mravčík, Hélène Peyière.

## 453 **FUNDING**

454 T.D.B. was supported by the Dalhousie University Internal Medicine Research Foundation Fellowship, a 455 Canadian Institutes of Health Research Fellowship (CIHR-FRN# 171259) and through the Research in 456 Addiction Medicine Scholars Program (National Institutes of Health/National Institute on Drug Abuse; 457 R25DA033211). For part of this work he was supported by the Killam Postgraduate Scholarship, Ross 458 Stewart Smith Memorial Fellowship in Medical Research and Clinician Investigator Program Graduate 459 Stipend (all from Dalhousie University Faculty of Medicine). T.D.B. is also principal investigator for CIHR-460 FRN# 185469). M.B., E.C. and I.K. were supported in this work via the Ross Stewart Smith Memorial 461 Fellowship in Medical Research (Principal Investigator: T.D.B.). D.L. was funded by a National Institute for Health Research Doctoral Research Fellowship (DRF-2018-11-ST2-016). M.H. was funded by a 462 463 National Institute for Health Research Career Development Fellowship (CDF-2016-09-014). M.F. was 464 funded by the National Institute of Drug Abuse (F31DA055345). The views expressed are those of the 465 authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. 466 These funders had no role in the conduct or reporting of the research.

It is made available under a CC-BY 4.0 International license .

# 467 **DECLARATION OF INTERESTS**

- 468 M.B. reports personal fees from AbbVie, a pharmaceutical research and development company, and
- 469 grants and personal fees from Gilead Sciences, a research-based biopharmaceutical company, outside of
- 470 the submitted work. The other authors report no competing interests.

It is made available under a CC-BY 4.0 International license .

# 471 **REFERENCES**

- Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injectingrelated injury and disease among people who inject drugs. Drug Alcohol Depend. 2017 Feb 1;171:39–49. https://doi.org/10.1016/j.drugalcdep.2016.11.029
- Gomes T, Kitchen SA, Tailor L, Men S, Murray R, Bayoumi AM, et al. Trends in Hospitalizations for
   Serious Infections Among People With Opioid Use Disorder in Ontario, Canada. Journal of
   Addiction Medicine. 2022 Aug;16(4):433–9. https://doi.org/10.1097/adm.00000000000928
- Colledge-Frisby S, Jones N, Larney S, Peacock A, Lewer D, Brothers TD, et al. The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. Drug and Alcohol Dependence. 2022;236:109494.
   https://doi.org/10.1016/j.drugalcdep.2022.109494
- See I, Gokhale RH, Geller A, Lovegrove M, Schranz A, Fleischauer A, et al. National Public Health
   Burden Estimates of Endocarditis and Skin and Soft-Tissue Infections Related to Injection Drug
   Use: A Review. The Journal of Infectious Diseases. 2020 Oct 1;222(Supplement\_5):S429–36.
   https://doi.org/10.1093/infdis/jiaa149
- 486 5. Lewer D, Brothers TD, Croxford S, Desai M, Emanuel E, Harris M, et al. Opioid injection-associated
  487 bacterial infections in England, 2002-2021: a time series analysis of seasonal variation and the
  488 impact of COVID-19. Clinical Infectious Diseases. 2023 Mar 14;ciad144.
  489 https://doi.org/10.1093/cid/ciad144
- 4906.Robertson R, Broers B, Harris M. Injecting drug use, the skin and vasculature. Addiction. 2021491Jul;116(7):add.15283. https://doi.org/10.1111/add.15283
- 492 7. Stein MD, Phillips KT, Herman DS, Keosaian J, Stewart C, Anderson BJ, et al. Skin-cleaning among
  493 hospitalized people who inject drugs: a randomized controlled trial. Addiction. 2021
  494 May;116(5):1122–30. https://doi.org/10.1111/add.15236
- Phillips KT, Stewart C, Anderson BJ, Liebschutz JM, Herman DS, Stein MD. A randomized
   controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections among
   people who inject drugs. Drug and Alcohol Dependence. 2021 Feb 27;108646.
   https://doi.org/10.1016/j.drugalcdep.2021.108646
- 8. Roux P, Donadille C, Magen C, Schatz E, Stranz R, Curado A, et al. Implementation and evaluation
  of an educational intervention for safer injection in people who inject drugs in Europe: a multicountry mixed-methods study. Int J Drug Policy. 2021 Jan;87:102992.
  https://doi.org/10.1016/j.drugpo.2020.102992
- Brothers TD, Bonn M, Lewer D, Comeau E, Kim I, Webster D, et al. Social and structural
   determinants of injection drug use-associated bacterial and fungal infections: a qualitative
   systematic review and thematic synthesis. Addiction. 2023 Oct;118(10):1853–77.
   https://doi.org/10.1111/add.16257

507 508 509	11.	Harris RE, Richardson J, Frasso R, Anderson ED. Experiences with skin and soft tissue infections among people who inject drugs in Philadelphia: A qualitative study. Drug and Alcohol Dependence. 2018 Jun 1;187:8–12. https://doi.org/10.1016/j.drugalcdep.2018.01.029
510 511 512	12.	Dunleavy K, Hope V, Roy K, Taylor A. The experiences of people who inject drugs of skin and soft tissue infections and harm reduction: A qualitative study. Int J Drug Policy. 2019;65:65–72. https://doi.org/10.1016/j.drugpo.2018.09.001
513 514 515 516	13.	Harris M, Scott J, Hope V, Wright T, McGowan C, Ciccarone D. Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London. Harm Reduct J. 2020 Apr 10;17(1):24. https://doi.org/10.1186/s12954-020-00369-0
517 518 519 520	14.	Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis. PLoS ONE. 2022 Jan 26;17(1):e0263156. https://doi.org/10.1371/journal.pone.0263156
521 522 523	15.	Chan Carusone S, Guta A, Robinson S, Tan DH, Cooper C, O'Leary B, et al. "Maybe if I stop the drugs, then maybe they'd care?"—hospital care experiences of people who use drugs. Harm Reduction Journal. 2019 Feb 13;16(1):16. https://doi.org/10.1186/s12954-019-0285-7
524 525 526	16.	Strike C, Robinson S, Guta A, Tan DH, O'Leary B, Cooper C, et al. Illicit drug use while admitted to hospital: Patient and health care provider perspectives. PLOS ONE. 2020 Mar 5;15(3):e0229713. https://doi.org/10.1371/journal.pone.0229713
527 528 529	17.	Harris M. Normalised pain and severe health care delay among people who inject drugs in London: Adapting cultural safety principles to promote care. Soc Sci Med. 2020 Sep 1;260:113183. https://doi.org/10.1016/j.socscimed.2020.113183
530 531 532	18.	Gilbert AR, Hellman JL, Wilkes MS, Rees VW, Summers PJ. Self-care habits among people who inject drugs with skin and soft tissue infections: a qualitative analysis. Harm Reduct J. 2019 Dec 12;16(1):69. https://doi.org/10.1186/s12954-019-0345-z
533 534 535	19.	Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug and Alcohol Dependence. 2019 May 1;198:80–6. https://doi.org/10.1016/j.drugalcdep.2019.01.037
536 537	20.	An KR, Luc JGY, Tam DY, Dagher O, Eikelboom R, Bierer J, et al. Infective endocarditis secondary to injection drug use: A survey of Canadian cardiac surgeons. Ann Thorac Surg. 2020 Dec 21;
538 539 540 541	21.	McNeil R, Small W, Wood E, Kerr T. Hospitals as a "risk environment": An ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014 Mar;105:59–66. https://doi.org/10.1016/j.socscimed.2014.01.010
542 543 544	22.	Lennox R, Martin L, Brimner C, O'Shea T. Hospital policy as a harm reduction intervention for people who use drugs. International Journal of Drug Policy. 2021 Nov 1;97:103324. https://doi.org/10.1016/j.drugpo.2021.103324

545 546 547 548	23.	Harris M, Holland A, Lewer D, Brown M, Eastwood N, Sutton G, et al. Barriers to management of opioid withdrawal in hospitals in England: a document analysis of hospital policies on the management of substance dependence. BMC Medicine. 2022 Apr 14;20(1):151. https://doi.org/10.1186/s12916-022-02351-y
549 550 551 552	24.	Hyshka E, Morris H, Anderson-Baron J, Nixon L, Dong K, Salvalaggio G. Patient perspectives on a harm reduction-oriented addiction medicine consultation team implemented in a large acute care hospital. Drug and Alcohol Depend. 2019 Nov 1;204:107523. https://doi.org/10.1016/j.drugalcdep.2019.06.025
553 554 555	25.	Brothers TD, Fraser J, MacAdam E, Hickcox S, L Genge, T O'Donnell, et al. Implementation and evaluation of a novel, unofficial, trainee-organized hospital addiction medicine consultation service. Subst Abus. 2021;42(4):433–7. https://doi.org/10.1080/08897077.2020.1856291
556 557 558 559	26.	Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, et al. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. Lancet Public Health. 2022 Jan;7(1):e56–64. https://doi.org/10.1016/s2468- 2667(21)00248-6
560 561 562 563	27.	Lewer D, Brothers TD, Harris M, Rock KL, Copeland CS. Opioid-related deaths during hospital admissions or shortly after discharge in the United Kingdom: A thematic framework analysis of coroner reports. PLOS ONE. 2023 Apr 19;18(4):e0283549. https://doi.org/10.1371/journal.pone.0283549
564 565 566	28.	Lewer D, Eastwood B, White M, Brothers TD, McCusker M, Copeland C, et al. Fatal opioid overdoses during and shortly after hospital admissions in England: case-crossover study. PLoS Med. 2021 Oct 5;18(10):e1003759. https://doi.org/10.1371/journal.pmed.1003759
567 568 569 570	29.	Brothers TD, Lewer D, Jones N, Colledge-Frisby S, Farrell M, Webster D, et al. Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: a cohort study in New South Wales, Australia. PLOS Medicine. 2022;19(7):e1004049. https://doi.org/10.1371/journal.pmed.1004049
571 572 573	30.	Barocas JA, Gai MJ, Amuchi B, Jawa R, Linas BP. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020;215:108207. https://doi.org/10.1016/j.drugalcdep.2020.108207
574 575 576 577	31.	Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010 Jul 24;376(9737):285–301. https://doi.org/10.1016/s0140-6736(10)60742- 8
578 579 580	32.	Perlman DC, Jordan AE. The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions. Curr HIV/AIDS Rep. 2018 Apr 1;15(2):96–112. https://doi.org/10.1007/s11904-018-0390-3
581 582	33.	Collins AB, Boyd J, Cooper HLF, McNeil R. The intersectional risk environment of people who use drugs. Soc Sci Med. 2019 Aug 1;234:112384. https://doi.org/10.1016/j.socscimed.2019.112384

583 584 585	34.	Rhodes T. The 'risk environment': a framework for understanding and reducing drug-related harm. International Journal of Drug Policy. 2002 Jun 1;13(2):85–94. https://doi.org/10.1016/S0955-3959(02)00007-5
586 587 588	35.	Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013 May 7;10(1):7. https://doi.org/10.1186/1477-7517-10-7
589 590 591	36.	Bluthenthal RN. Structural racism and violence as social determinants of health: Conceptual, methodological and intervention challenges. Drug and Alcohol Dependence. 2021 May;222:108681. https://doi.org/10.1016/j.drugalcdep.2021.108681
592 593 594 595	37.	Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies systematic review. BMJ Open. 2021 Aug 9;11(8):e049924. http://doi.org/10.1136/bmjopen-2021-049924
596 597 598	38.	Pluye P, Hong QN. Combining the Power of Stories and the Power of Numbers: Mixed Methods Research and Mixed Studies Reviews. Annu Rev Public Health. 2014;35(1):29–45. https://doi.org/10.1146/annurev-publhealth-032013-182440
599 600 601 602	39.	Dekkers OM, Vandenbroucke JP, Cevallos M, Renehan AG, Altman DG, Egger M. COSMOS-E: Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. PLOS Medicine. 2019 Feb 21;16(2):e1002742. https://doi.org/10.1371/journal.pmed.1002742
603 604 605	40.	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. https://doi.org/10.1136/bmj.n71
606 607 608	41.	Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, et al. Conducting systematic reviews of association (etiology): The Joanna Briggs Institute's approach. JBI Evidence Implementation. 2015 Sep;13(3):163–9. https://doi.org/10.1097/xeb.000000000000064
609 610 611	42.	Lett E, Asabor E, Beltrán S, Cannon AM, Arah OA. Conceptualizing, Contextualizing, and Operationalizing Race in Quantitative Health Sciences Research. Ann Fam Med. 2022;20(2):157– 63. https://doi.org/10.1370/afm.2792
612 613	43.	Kaufman JS. Commentary: Causal Inference for Social Exposures. Annual Review of Public Health. 2019;40(1):7–21. https://doi.org/10.1146/annurev-publhealth-040218-043735
614 615 616	44.	Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing Meta-Analysis in R [Internet]. Boca Raton, FL and London: Chapman & Hall/CRC Press; 2021. https://bookdown.org/MathiasHarrer/Doing_Meta_Analysis_in_R/
617 618 619 620	45.	Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Education for Information. 2018 Jan 1;34(4):285–91. https://content.iospress.com/articles/education-for- information/efi180221

621 622 623	46.	Hong QN, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed Methods Appraisal Tool (MMAT) Version 2018: User Guide [Internet]. Montreal, Canada: McGill University; 2018 Aug.
624 625		http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/127916259/MMAT_2018_cri teria-manual_2018-08-01_ENG.pdf
626 627	47.	DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986 Sep 1;7(3):177–88. https://doi.org/10.1016/0197-2456(86)90046-2
628 629	48.	Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Statistics in Medicine. 2003;22(17):2693–710. https://doi.org/10.1002/sim.1482
630 631	49.	Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 4;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557
632 633	50.	Viechtbauer W, Cheung MWL. Outlier and influence diagnostics for meta-analysis. Research Synthesis Methods. 2010;1(2):112–25. https://doi.org/10.1002/jrsm.11
634 635 636	51.	Bourgois P, Bruneau J. Needle exchange, HIV infection, and the politics of science: Confronting Canada's cocaine injection epidemic with participant observation. Medical Anthropology. 2000 Jan 1;18(4):325–50. https://doi.org/10.1080/01459740.2000.9966161
637 638 639	52.	Bourgois P. Anthropology and epidemiology on drugs: the challenges of cross-methodological and theoretical dialogue. International Journal of Drug Policy. 2002 Oct 1;13(4):259–69. https://doi.org/10.1016/S0955-3959(02)00115-9
640 641 642	53.	Hyshka E, Strathdee S, Wood E, Kerr T. Needle exchange and the HIV epidemic in Vancouver: Lessons learned from 15 years of research. International Journal of Drug Policy. 2012 Jul 1;23(4):261–70. https://doi.org/10.1016/j.drugpo.2012.03.006
643 644 645 646	54.	Roux P, Jauffret-Roustide M, Donadille C, Briand Madrid L, Denis C, Célérier I, et al. Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort. International Journal of Epidemiology. 2023 Apr 1;52(2):562–76. https://doi.org/10.1093/ije/dyac120
647 648 649 650 651	55.	Brothers TD, Lewer D, Jones N, Colledge-Frisby S, Bonn M, Wheeler A, et al. Effect of incarceration and opioid agonist treatment transitions on risk of hospitalisation with injection drug use-associated bacterial infections: A self-controlled case series in New South Wales, Australia. International Journal of Drug Policy. 2023 Dec 1;122:104218. https://doi.org/10.1016/j.drugpo.2023.104218
652 653 654	56.	Wurcel AG, Burke D, Skeer M, Landy D, Heimer R, Wong JB, et al. Sex work, injection drug use, and abscesses: Associations in women, but not men. Drug Alcohol Depend. 2018 Apr 1;185:293– 7.
655 656 657	57.	Sheard L, Tompkins C. Contradictions and Misperceptions: An Exploration of Injecting Practice, Cleanliness, Risk, and Partnership in the Lives of Women Drug Users. Qual Health Res. 2008 Nov 1;18(11):1536–47. https://doi.org/10.1177/1049732308325838

658 659 660	58.	Fairbairn N, Small W, Van Borek N, Wood E, Kerr T. Social structural factors that shape assisted injection drug users in Vancouver, Canada: a qualitative study. Harm Reduction Journal. 2010 Aug 31;7(1):20. https://doi.org/10.1186/1477-7517-7-20
661 662 663	59.	Wood E, Spittal PM, Kerr T, Small W, Tyndall MW, O'Shaughnessy MV, et al. Requiring Help Injecting as a Risk Factor for HIV Infection in the Vancouver Epidemic. Can J Public Health. 2003 Sep;94(5):355–9. https://doi.org/10.1007/bf03403560
664 665 666	60.	Collins AB, Boyd J, Czechaczek S, Hayashi K, McNeil R. (Re)shaping the self: An ethnographic study of the embodied and spatial practices of women who use drugs. Health & Place. 2020 May 1;63:102327. https://doi.org/10.1016/j.healthplace.2020.102327
667 668 669	61.	Collins AB, Boyd J, Hayashi K, Cooper HLF, Goldenberg S, McNeil R. Women's utilization of housing-based overdose prevention sites in Vancouver, Canada: An ethnographic study. Int J Drug Policy. 2020 Feb;76:102641. https://doi.org/10.1016/j.drugpo.2019.102641
670 671 672	62.	Boyd J, Collins AB, Mayer S, Maher L, Kerr T, McNeil R. Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada. Addiction. 2018;113(12):2261–70. https://doi.org/10.1111/add.14417
673 674 675	63.	Summers PJ, Struve IA, Wilkes MS, Rees VW. Injection-site vein loss and soft tissue abscesses associated with black tar heroin injection: A cross-sectional study of two distinct populations in USA. Int J Drug Policy. 2017 Jan;39:21–7. https://doi.org/10.1016/j.drugpo.2016.08.006
676 677 678	64.	Ciccarone D, Unick GJ, Cohen J, Mars SG, Rosenblum D. Nationwide Increase in Hospitalizations for Heroin-related Soft Tissue Infections: Associations with Structural Market Conditions. Drug Alcohol Depend. 2016 Jun 1;163:126–33. https://doi.org/10.1016/j.drugalcdep.2016.04.009
679 680 681	65.	Ciccarone D, Harris M. Fire in the vein: Heroin acidity and its proximal effect on users' health. International Journal of Drug Policy. 2015 Nov 1;26(11):1103–10. https://doi.org/10.1016/j.drugpo.2015.04.009
682 683 684 685	66.	Harris M, Scott J, Wright T, Brathwaite R, Ciccarone D, Hope V. Injecting-related health harms and overuse of acidifiers among people who inject heroin and crack cocaine in London: a mixed- methods study. Harm Reduct J. 2019 Nov 13;16(1):60. https://doi.org/10.1186/s12954-019-0330- 6
686 687 688	67.	Lambdin BH, Bluthenthal RN, Zibbell JE, Wenger L, Simpson K, Kral AH. Associations between perceived illicit fentanyl use and infectious disease risks among people who inject drugs. Int J Drug Policy. 2019 Dec;74:299–304. https://doi.org/10.1016/j.drugpo.2019.10.004
689 690 691	68.	Kenny KS, Kolla G, Greig S, Bannerman M, Phillips D, Altenberg J, et al. Association of Illicit Fentanyl Use with Injection Risk Practices Among People who Inject Drugs. AIDS Behav. 2023 Jun 1;27(6):1757–65. https://doi.org/10.1007/s10461-022-03908-x
692 693 694 695	69.	Benrubi LM, Silcox J, Hughto J, Stopka TJ, Palacios WR, Shrestha S, et al. Trends and correlates of abscess history among people who inject drugs in Massachusetts: A mixed methods exploration of experiences amidst a rapidly evolving drug supply. Drug and Alcohol Dependence Reports. 2023 Sep 1;8:100176. https://doi.org/10.1016/j.dadr.2023.100176

It is made available under a CC-BY 4.0 International license .

696 697 698	70.	Lloyd M, Ransom EM, Anderson NW, Farnsworth CW. Evaluation of Infectious Disease Test Ordering and Positivity Rates in Illicit Fentanyl Users. The Journal of Applied Laboratory Medicine. 2021 Jan 12;6(1):79–92. https://doi.org/10.1093/jalm/jfaa194
699 700 701	71.	Harvey LH, Green TC, Park JN, Rich JD. Xylazine in the drug supply: A research agenda. International Journal of Drug Policy. 2023 Oct 1;120:104190. https://doi.org/10.1016/j.drugpo.2023.104190
702 703 704	72.	Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduction Journal. 2023 Sep 30;20(1):141. https://doi.org/10.1186/s12954-023-00879-7
705 706 707	73.	Kenney SR, Phillips KT, Herman DS, Keosaian J, Anderson BJ, Stein MD. Perceived Behavioral Control and Barriers to Cleaning Skin Before Injecting Drugs. Journal of Addiction Medicine. 2020 Jun;14(3):231–5. https://doi.org/10.1097/adm.0000000000000564
708 709 710 711	74.	Kimmel SD, Phillips KT, Anderson BJ, Stein MD. Characteristics associated with motivation to stop substance use and improve skin and needle hygiene among hospitalized patients who inject drugs. Substance Abuse. 2022 Dec 1;43(1):878–83. https://doi.org/10.1080/08897077.2021.2007520
712 713 714	75.	Varga LM, Chitwood DD, Fernandez MI. Research note: Factors associated with skin cleaning prior to injection among drug users. J Drug Issues. 2006;36(4):1015–30. https://doi.org/10.1177/0022042606036004

Exposure	Unadjusted Odds Ratio (95% Cl)	No. of Studies	Adjusted Odds Ratio (95% Cl)	No. of Studies	Odds Ratios (95% CI)
Demographic characteristics	(,		(,		
Gender/sex (womean/female)	1.56 (1.34-1.82)	27	1.57 (1.36-1.83)	20	*
Age (older)	1.00 (0.99-1.01)	32	1.00 (0.89-1.10)	20	
Race/ethnicity (white)	1.14 (0.90-1.44)	17	1.15 (0.92-1.44)	11	
Education (more)	0.87 (0.76-0.99)	9	0.86 (0.13-5.55)	4	<b>*</b>
Income/employment (unemployed/low income)	1.44 (1.22-1.71)	16	1.16 (0.81-1.65)	7	<b>_</b>
Relationship status (married)	0.61 (0.00-377.00)	2	0.38 (0.17-0.85)	1	$\leftarrow$
Migration status (born outside UK)	1.20 (0.80-1.60)	1		0	
Social and housing support characteristics					
Incarceration history (yes)	1.27 (1.06-1.53)	6	1.60 (0.99-2.59)	2	
Sex work (yes)	1.44 (1.06-2.09)	9	1.58 (0.72-3.50)	6	
Unstable housing/homelessness (yes)	1.34 (1.20-1.49)	29	1.29 (1.16-1.45)	13	*
Food insecurity (yes)	1.76 (0.84-3.68)	1		0	
Health insurance (Medicaid vs. other)	0.79 (0.18-3.56)	1		0	
Substance use					
Overdose history (yes)	2.28 (0.42-12.26)	2	1.87 (0.25-14.06)	2	<b>_</b> •>
Heroin formulation (tar vs. powder)	7.44 (0.31-176.41)	2	3.65 (0.00-15058.18)	2	← ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Heroin injecting (any/frequent vs. none/less)	1.53 (1.29-1.82)	20	1.28 (0.95-1.74)	7	_ <u>_</u>
Cocaine injecting, all types (any/frequent vs. none/less)	1.42 (1.25-1.61)	27	1.31 (1.02-1.69)	10	*
Crack (base) cocaine injecting (any/frequent vs. none/less)	1.55 (1.33-1.80)	9	1.30 (0.80-2.13)	3	<b>_</b>
Powder (hydrochloride) cocaine injecting (any/frequent vs. none/less)	1.35 (1.00-1.83)	7	1.78 (1.14-2.78)	1	
Amphetamine injecting (any/frequent vs. none/less)	0.90 (0.54-1.48)	11	1.74 (1.39-2.23)	2	
Methylphenidate injecting (any/frequent vs. none/less)	0.73 (0.19-2.82)	2	. ,	0	
Speedball or goofball injecting (any/frequent vs. none/less)	1.34 (1.15-1.57)	12	1.35 (0.38-4.77)	2	
Alcohol use (any/hazardous vs. none/less)	0.94 (0.77-1.14)	7	0.59 (0.13-2.67)	3	
Drug policy and injecting context			·····		
Injecting in public (yes)	1.54 (1.27-1.86)	4	1.40 (1.05-1.88)	2	
Shooting gallery use (yes)	0.84 (0.17-4.02)	2	1.33 (0.31-5.73)	1	
Police contacts and arrest history (yes)	1.16 (0.85-1.59)	9	1.19 (0.61-2.31)	4	
Assisted injecting (receiving or requiring vs. not)	2.09 (1.61-2.71)	8	1.78 (1.40-2.27)	8	_ <b>_</b>
Injecting with others (yes)	1.44 (0.88-2.34)	7	2.55 (0.01-769.91)	2	← →
Harm reduction and drug treatment			. ,		
Needle and syringe program use (any/frequent vs. none/less)	0.75 (0.54-1.05)	7	0.75 (0.54-1.03)	6	-
Opioid agonist treatment (current/recent vs. not)	0.71 (0.62-0.81)	10	0.92 (0.89-0.95)	9	-
Supervised consumption site use (any/frequent vs. none/less)	0.74 (0.17-3.26)	3	0.59 (0.29-1.19)	1	<b>_</b>

0.1 0.2 0.5 1 2 5 10

Study	Unadjusted Odds Ratio Weight (95% CI)	Adjusted Odds Ratio We (95% Cl)	eight	Homelessness or unstable housing	Study	Unadjus Odds Ra (95% C	atio Weight	Adjus Odds F (95%	Ratio V	Veight	Incarceration history
Wilson 2002	0.78 (0.46-1.32) 3%	(00)000			Lloyd-Smith 2005	1.65 (1.30-	-2.10) 16%	1.69 (1.3		30%	
Lloyd-Smith 2005	1.41 (1.10-1.80) 7%				Hope 2010	1.00 (0.87-	-1.13) 20%				
Sierra 2006	4.33 (1.50-12.50) 1%				Hope 2010	1.00 (0.87	-1.13) 20%				Ī
Hope 2008	1.54 (1.10-2.17) 5%				Milloy 2010	1.56 (1.32-	-1.85) 18%	1.56 (1.3	1-1.85)	70%	-
Lloyd-Smith 2008	1.56 (1.15-2.12) 6%	1.49 (1.10-2.03) 9	1%		Pollini 2010	1.31 (0.88-	-1.94) 11%				
Phillips 2008	1.00 (0.43-2.32) 1%	1.00 (0.43-2.33) 1	%			1.01 (0.00	1.54) 1176				
Lloyd-Smith 2009	1.61 (1.17-2.22) 5%	1.38 (1.02-1.88) 9	1%		Dunleavy 2017	1.03 (0.83-	-1.28) 17%				
Hope 2010	1.23 (1.08-1.41) 10%	1.18 (1.05-1.33) 3	8%	*	Doran 2020	1.28 (1.10-	-1.50) 19%				
Lloyd-Smith 2010	1.65 (1.08-2.53) 4%	1.26 (0.79-2.02) 4	%		Doran Long		1070				
Milloy 2010	1.24 (0.98-1.56) 7%	1.30 (1.01-1.67) 13	3%								
Phillips 2010	1.22 (0.35-4.27) 1%			· · · · · · · · · · · · · · · · · · ·	Random effects model	1.27 (1.06-	-1.53)	1.60 (0.9	9-2 59)		
Pollini 2010	1.74 (0.71-4.26) 1%							1.00 (0.0			
Lloyd-Smith 2012 (Men only)	1.60 (1.18-2.17) 6%	1.37 (0.98-1.92) 8	\$%		Heterogeneity		81%			0%	
Lloyd-Smith 2012 (Women only)	1.69 (1.09-2.61) 4%	1.12 (0.69-1.82) 4	%								
Hope 2014 (Cellulitis)	1.39 (0.99-1.94) 5%										0.5 1 2 5
Hope 2015 (Cellulitis)	1.36 (1.04-1.78) 6%	2.17 (1.36-3.45) 4	%								Odds Ratios (95% CI)
Smith 2015	0.80 (0.30-2.14) 1%										
Betts 2016	1.39 (0.97-1.99) 7%				120		Unadjusted		Adjusted		
Dahlman 2017	1.26 (0.49-3.23) 1%			•	Study		Odds Ratio V (95% CI)	Neight	Odds Ratio (95% CI)	o Weig	ht Needle and syringe program use
Phillips 2017	0.78 (0.39-1.56) 2%	0.53 (0.22-1.27) 1	%		Binswanger 2000		0.94 (0.40-2.20)	6%	(00% 01)		
Summers 2017	3.09 (1.53-6.24) 2%	1.37 (0.38-4.94) 1	%		Fink 2013		1.02 (0.76-1.37)	10%	).91 (0.65-1.2	27) 20	24
Wurcel 2018 (Men only)	0.68 (0.30-1.56) 1%								0.91 (0.03-1.4	27) 20	
Wurcel 2018 (Women only)	2.34 (0.77-7.12) 1%	1.99 (0.48-8.27) 0	1%	<b>_</b> ••→>	Dunleavy 2017 (Needle and syr	inge uptake)	0.65 (0.53-0.80)	22% 0	0.72 (0.58-0.8	39) 28	%
Baltes 2020	0.80 (0.27-2.38) 1%				Dunleavy 2017 (Other equipme	nt uptake)	0.71 (0.58-0.87)	23% 0	0.77 (0.63-0.9	95) 299	%
Doran 2020 (C&P)	1.23 (0.80-1.90) 4%				Wurcel 2018 (Men only)		1.43 (0.80-2.56)	10%		201 70	
Doran 2020 (UAM)	1.10 (1.00-1.20) 11%				Wulcei 2018 (Merroniy)		1.43 (0.80-2.56)	10%	1.31 (0.65-2.0	53) 7%	
Roux 2020	2.22 (1.19-4.15) 2%				Wurcel 2018 (Women only)		0.49 (0.19-1.24)	5% 0	).27 (0.07-1.0	01) 2%	
Shah 2020	1.38 (0.61-3.11) 1%				Noroozi 2019		0.46 (0.30-0.71)	14%	0.50 (0.32-0.3	78) 149	%
Thonnings 2020	0.74 (0.38-1.45) 2%									•,	
Wright 2020	1.24 (0.79-1.96) 3%										
					Random effects model		0.75 (0.54-1.05)	C	0.75 (0.54-1.0	03)	
Random effects model	1.34 (1.20-1.49)	1.29 (1.16-1.44)		-	Heterogeneity			64%		47	No.
Heterogeneity	43%	9	9%		,			0.70		41	
			0.2	2 0.5 1 2 5							
				Odds Ratios (95% CI)							0.2 0.5 1 2 5 Odds Ratios (95% CI)

